ClinicalTrials.gov
ClinicalTrials.gov Menu

Prize Contingency Management for Cocaine-Dependent Methadone Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01401270
Recruitment Status : Active, not recruiting
First Posted : July 25, 2011
Last Update Posted : May 9, 2018
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Nancy Petry, UConn Health

Brief Summary:
The investigators will randomize 300 cocaine-dependent methadone patients to 1 of 6 conditions: (a) a control group, (b) a contingency management condition that arranges a 100% probability of winning a prize with each draw and has 3 prize categories, (c) a contingency management condition that arranges a 31% probability of winning and has 3 prize categories, (d) a contingency management condition that arranges a 100% probability of winning and has 7 prize categories, (e) a contingency management condition that arranges a 31% probability of winning and has 7 prize categories, or (f) usual prize contingency management with a 50% probability of winning from 3 prize categories. Magnitudes of reinforcement will be identical across conditions, but lower overall probability conditions arrange for greater chances of winning larger magnitude prizes. The investigators expect that the new contingency management conditions will reduce cocaine use relative to the control condition, that 31% probability conditions will decrease drug use relative to 100% conditions, and that 7-prize category conditions will reduce drug use compared to 3-prize category conditions. In addition, the 31%/7-category condition is expected to be most efficacious. Results will be instrumental for further developing prize contingency management to improve outcomes of cocaine-dependent methadone patients.

Condition or disease Intervention/treatment Phase
Cocaine Abuse Behavioral: prize contingency management Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prize Contingency Management for Cocaine-Dependent Methadone Patients
Actual Study Start Date : November 2011
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Treatment Group A
Standard Care
Experimental: Treatment Group B
100% probability of winning a prize with each draw and has 3 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Experimental: Treatment Group C
31% probability of winning and has 3 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Experimental: Treatment Group D
100% probability of winning and has 7 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Experimental: Treatment Group E
31% probability of winning and has 7 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Experimental: Treatment Group F
usual prize contingency management with a 50% probability of winning from 3 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.




Primary Outcome Measures :
  1. longest continuous period of cocaine abstinence [ Time Frame: three months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age > 18 years
  • current DSM-IV diagnosis of cocaine dependence
  • enrolled at the clinic for >3 months
  • on a stable dose of methadone (no changes) for >1 month and not requesting a dose alteration
  • submitted >1 clinic cocaine positive sample in the last 6 months
  • English speaking
  • pass a quiz related to understanding the informed consent form

Exclusion Criteria:

  • serious, uncontrolled psychiatric illness
  • significant cognitive impairment
  • in recovery from pathological gambling

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01401270


Locations
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
UConn Health
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Sheila M Alessi, Ph.D. UConn Health

Responsible Party: Nancy Petry, Professor, UConn Health
ClinicalTrials.gov Identifier: NCT01401270     History of Changes
Other Study ID Numbers: 10-256-2
R01DA013444 ( U.S. NIH Grant/Contract )
First Posted: July 25, 2011    Key Record Dates
Last Update Posted: May 9, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Methadone
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Analgesics, Opioid
Narcotics
Analgesics
Antitussive Agents
Respiratory System Agents